Marc Brehme

Trained at the Universities of Heidelberg (DE) and Manchester (UK), the German Cancer Research Center (DKFZ), European Molecular Biology Laboratory (EMBL), and CeMM – Center for Molecular Medicine of the Austrian Academy of Sciences (AT), he obtained his Ph.D. in Molecular Biology from the University of Vienna (AT) in 2009 with Prof. Giulio Superti-Furga, serial entrepreneur, CEO and Director of the CeMM.

Dr. Brehme held Postgraduate Research Fellowships at Dana-Farber Cancer Institute (DFCI), Harvard Medical School (Boston, USA) and Northwestern University (Chicago, USA), and his research is cited > 3,000 times. He is recipient of a Joachim Herz Foundation Fellowship (2016) and the PLoS Computational Biology Research Prize (2019).

Dr. Brehme served on editorial and biotech non-profit executive boards, including the European Federation of Biotechnology (EFB). He unites an international track record as scientist with experience as Group Leader at RWTH Aachen (DE) (2015-2017, Bayer-funded), and with industry experience in several international biotech companies Cellzome GmbH (GER) (now GSK), Proteostasis Therapeutics Inc. (USA), CBmed GmbH (AT), and Ribbon Bio GmbH (AT).

As biotech manager and entrepreneur, he drove the growth of successful startups. At CBmed, he held management positions as Director Business Development and Head of Systems Biology & IT, served on the Scientific Board, managed a 4-year centre funding extension of 18,5 Mio €, and closed deals with big pharma clients and tech partners. At Ribbon Bio in Vienna Dr. Brehme gained C-level experience as Chief Technology Officer (CTO) and Co-Managing Director 2019-2023, built and developed the company from pre-seed to early market, and lead tech development towards robotic automated commercial DNA synthesis. He co-led Ribbon’s 18 Mio € Series A investment (2023) and successfully led multi-Mio € CapEx projects, uniting management experience with strategic and operational strengths.

Between 2021 - 2023 he pursued an MBA in Strategic Management & Technology at Vienna University of Technology (TU Wien) for which he was awarded an Emerging Leaders Scholarship (2021) and Best Study Award (2023).

Within the BioExpert Network, Dr. Brehme acts as evaluator of biotech start-up CapitalCell investment applications. He teaches biotech entrepreneurship as Lecturer at the University of Applied Sciences Campus Vienna (AT).

As Founder of his venture consultancy M-B-V-C he is helping ventures take flight since 2023. Between 2024-2025, Dr. Brehme served as fractional Chief Business Officer (CBO) at the Vienna-based 3D-bioprinting start-up company Biomotion Technologies FlexCo and he is currently supporting pharmaceutical and medtech companies of different sizes.